News Headlines Article

Marquee names, $53M push startup into showdown with defiant cancers
San Francisco Business Times

Serial entrepreneur Rich Heyman and venture capital firm The Column Group are getting the cancer-fighting band back together, pulling in $53 million to find drugs for patients whose cancers find new, deadly pathways. The Series B round of cash will help year-old ORIC Pharmaceuticals Inc. of South San Francisco take at least one drug into a human clinical trial in about two years.